Shay Capital LLC Invests $233,000 in Zura Bio Limited (NASDAQ:ZURA)

Shay Capital LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 93,119 shares of the company’s stock, valued at approximately $233,000.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. bought a new position in shares of Zura Bio during the fourth quarter worth about $27,000. Prudential Financial Inc. bought a new position in shares of Zura Bio during the fourth quarter worth about $28,000. ProShare Advisors LLC bought a new position in shares of Zura Bio during the fourth quarter worth about $35,000. XTX Topco Ltd bought a new position in shares of Zura Bio during the fourth quarter worth about $44,000. Finally, SG Americas Securities LLC raised its position in shares of Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital lowered their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Finally, Oppenheimer lowered their target price on Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, May 9th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zura Bio currently has an average rating of “Buy” and a consensus target price of $14.33.

Zura Bio Stock Performance

Shares of ZURA stock opened at $1.11 on Friday. Zura Bio Limited has a fifty-two week low of $0.97 and a fifty-two week high of $6.35. The stock has a 50 day simple moving average of $1.28 and a two-hundred day simple moving average of $1.99. The company has a market cap of $75.90 million, a P/E ratio of -1.59 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, research analysts predict that Zura Bio Limited will post -0.65 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.